Aion Therapeutic Inc. announced on February 17th 2021 the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol and other drug misuse), depression and anxiety associated with life-threatening illnesses, and treatment-resistant depression. In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.

The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University if the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.

Recent News

Get the atai
Investor’s Kit now.

Compounds

Market Cap

CSE: AION

Focus

Social